OBJECTIVE: To evaluate the efficacy of mycophenolate mofetil (MMF) in chronic inflammatory demyelinating polyneuropathy (CIDP). BACKGROUND: Evidence is growing that MMF is effective as an immunomodulatory drug in neuromuscular diseases. METHODS: A database of 184 patients with CIDP was analysed to obtain clinical, laboratory and electrophysiological information for patients with CIDP treated with MMF. RESULTS: Eight patients, who met the inclusion criteria, received MMF (mean dose 2 g/day; median duration 15.2 months). The average Neuropathy Impairment Score of the eight patients improved from baseline (72.3+/-35) after initiation of MMF therapy (37.8+/-37; p<0.001). Six of these eight patients were either able to stop concomitant medications (corticosteroid, intravenous immunoglobulin) or reduce their doses and frequency by > or = 50%. CONCLUSIONS: Our pilot data suggest that MMF appears to be an effective therapy for patients with naive or refractory CIDP, and further controlled studies are warranted for their confirmation.
OBJECTIVE: To evaluate the efficacy of mycophenolate mofetil (MMF) in chronic inflammatory demyelinating polyneuropathy (CIDP). BACKGROUND: Evidence is growing that MMF is effective as an immunomodulatory drug in neuromuscular diseases. METHODS: A database of 184 patients with CIDP was analysed to obtain clinical, laboratory and electrophysiological information for patients with CIDP treated with MMF. RESULTS: Eight patients, who met the inclusion criteria, received MMF (mean dose 2 g/day; median duration 15.2 months). The average Neuropathy Impairment Score of the eight patients improved from baseline (72.3+/-35) after initiation of MMF therapy (37.8+/-37; p<0.001). Six of these eight patients were either able to stop concomitant medications (corticosteroid, intravenous immunoglobulin) or reduce their doses and frequency by > or = 50%. CONCLUSIONS: Our pilot data suggest that MMF appears to be an effective therapy for patients with naive or refractory CIDP, and further controlled studies are warranted for their confirmation.
Authors: Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes Journal: Cochrane Database Syst Rev Date: 2017-05-08
Authors: Jacqueline Kerr; Isabella Quinti; Martha Eibl; Helen Chapel; Peter J Späth; W A Carrock Sewell; Abdulgabar Salama; Ivo N van Schaik; Taco W Kuijpers; Hans-Hartmut Peter Journal: Front Immunol Date: 2014-12-12 Impact factor: 7.561